This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Waters, C. H. Search for Related Content PubMed Articles by Waters, C. H. Social Bookmarking                         What's this?

Side Effects of Selegiline (Eldepryl)

Department of Neurology, University of Southern California, Los Angeles, CA.

Selegiline (Eldepryl), recently approved as an adjunct to levodopa-carbidopa (Sinemet), was administered to eight patients with Parkinson's disease in an open-label study. Many side effects were seen pertinent in particular to the elderly patient. Urinary retention was precipitated in two gentlemen. We advise that this medication be used with caution in the parkinsonian patient. (J Geriatr Psychiatry Neurol 1992;5:31–34).

Journal of Geriatric Psychiatry and Neurology, Vol. 5, No. 1, 31-34 (1992)
DOI: 10.1177/002383099200500105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?